Delayed Pseudoprogression in Glioblastoma Patients Treated With Tumor-Treating Fields

被引:0
|
作者
Saito, Norihiko [1 ]
Hirai, Nozomi [1 ]
Sato, Sho [1 ]
Hayashi, Morito [1 ]
Iwabuchi, Satoshi [1 ]
机构
[1] Toho Univ, Neurosurg, Ohashi Med Ctr, Tokyo, Japan
关键词
electric fields; glioblastoma multiforme; temozolomide; radiation therapy; pseudoprogression; ttfields; glioblastoma; TEMOZOLOMIDE; RADIOTHERAPY; BEVACIZUMAB; TRIAL;
D O I
10.7759/cureus.55147
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor-treating fields (TTFields) is an established treatment modality for glioblastoma. False progression to chemoradiation is a known problem in patients with glioblastoma multiforme (GBM), with most cases occurring within three months of radiation therapy. In this report, we present two cases of delayed pseudoprogression caused by TTFields. Two patients with GBM who received TTFields showed signs of radiographic progression six months after the completion of radiation therapy. Patient 1 was a 37-year-old female with a glioblastoma in the right temporal lobe. Patient 2 was a 70-year-old male with glioblastoma in the left temporal lobe. Both patients received radiation therapy, followed by temozolomide (TMZ) maintenance therapy and TTFields. Patient 1 underwent a second resection; however, the pathology revealed only a treatment effect, and the final diagnosis was a pseudoprogression. In Case 2, the disease resolved with steroid therapy alone. In both patients, the lesions appeared later than during the typical pseudoprogression period. A recent study reported that TTFields increase the permeability of the plasma cell membrane, which may result in further leakage of gadolinium into the extracellular lumen. Further studies are needed to better characterize delayed pseudoprogression and improve treatment outcomes.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment
    Wang, Minjie
    Zhang, Chaocai
    Wang, Xuan
    Yu, Hao
    Zhang, Hemei
    Xu, Junnv
    Zhao, Jiannong
    Jiang, Xiaobing
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (04): : 1069 - 1086
  • [42] Prostaglandin E Receptor 3 Mediates Resistance to Tumor-Treating Fields in Glioblastoma Cells
    Chen, D.
    Le, S.
    Thomas, N.
    Tran, D. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E95 - E96
  • [43] TUMOR-TREATING FIELDS FOR GLIOBLASTOMA: NUMERICAL SIMULATION EXPLORES SUB-CELLULAR MECHANISMS
    Carlson, Kristen
    Paudel, Nirmal
    Dokos, Socrates
    Tuszynski, Jack
    NEURO-ONCOLOGY, 2018, 20 : 228 - 228
  • [44] Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial
    Cappelli, Louis
    Khan, Mehak Majid
    Kayne, Allison
    Poiset, Spencer
    Miller, Ryan
    Ali, Ayesha
    Niazi, Muneeb
    Shi, Wenyin
    Alnahhas, Iyad
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (03)
  • [45] CHEMORADIATION (CRT) TREATMENT WITH OR WITHOUT CONCURRENT TUMOR-TREATING FIELDS (TTFIELDS) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Cappelli, Louis
    Kayne, Allison
    Pan, Peter
    Cordova, James
    Huang, Jiayi
    Wang, Tony
    Alnahhas, Iyad
    Shi, Wenyin
    NEURO-ONCOLOGY, 2022, 24 : 53 - 53
  • [46] Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study
    Kanamori, Masayuki
    Tsuzuki, Shunsuke
    Shibahara, Ichiyo
    Saito, Kuniaki
    Shimoda, Yoshiteru
    Tanaka, Kazuhiro
    Yamaguchi, Shigeru
    Natsumeda, Manabu
    Matsutani, Tomoo
    Hanihara, Mitsuto
    Nakada, Mitsutoshi
    Kuroda, Jun-Ichiro
    Matsuda, Masahide
    Yoshimoto, Koji
    Yonezawa, Ushio
    Sonoda, Yukihiko
    Takano, Koji
    Yonezawa, Hajime
    Otani, Yoshihiro
    Nakahara, Yukiko
    Uchida, Masashi
    Nonaka, Masahiro
    Mineharu, Yohei
    Kitamura, Yohei
    Yamashita, Shinji
    Yamauchi, Takahiro
    Miyake, Yohei
    Deguchi, Shoichi
    Beppu, Takaaki
    Tamura, Kaoru
    Koizumi, Shinichiro
    Hirose, Yuichi
    Asano, Kenichiro
    Hiruta, Ryo
    Kinoshita, Manabu
    Miyake, Keisuke
    Nakayama, Noriyuki
    Inoue, Akihiro
    Ono, Takahiro
    Sasaki, Takahiro
    Akiyama, Yukinori
    Fukami, Shinjiro
    Yoshino, Atsuo
    Kawanishi, Yu
    Asanome, Taku
    Yamaguchi, Takuhiro
    Takahashi, Masamichi
    Yamasaki, Fumiyuki
    Arakawa, Yoshiki
    Narita, Yoshitaka
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [47] IMPACT OF MOLECULAR MARKERS ON TREATMENT OUTCOME OF GLIOBLASTOMA PATIENTS TREATED WITH CONCURRENT TUMOR-TREATING FIELDS (TTF) AND CHEMORADIATION: SECONDARY ANALYSIS OF SPARE TRIAL
    Cappelli, Louis
    Kayne, Allison
    Poiset, Spencer
    Niazi, Muneeb
    Ali, Ayesha
    Alnahhas, Iyad
    Shi, Wenyin
    NEURO-ONCOLOGY, 2022, 24 : 142 - 143
  • [48] REAL LIFE EXPERIENCE OF GLIOBLASTOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS.
    Belles, Lynn
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [49] A comment to improve tumor-treating fields therapy
    Fioranelli, Massimo
    Sepehri, Alireza
    AIMS BIOENGINEERING, 2023, 10 (01): : 13 - 23
  • [50] Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies
    Wang, Yuefeng
    Pandey, Manjari
    Ballo, Matthew T.
    ONCOLOGIST, 2019, 24 (12): : E1426 - E1436